| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphocytes, Tumor-Infiltrating | 32 | 2024 | 992 | 2.800 |
Why?
|
| Melanoma | 44 | 2023 | 5317 | 2.300 |
Why?
|
| CD8-Positive T-Lymphocytes | 20 | 2022 | 1586 | 1.490 |
Why?
|
| T-Lymphocytes | 19 | 2023 | 3869 | 1.190 |
Why?
|
| Antigens, Neoplasm | 8 | 2018 | 1506 | 1.090 |
Why?
|
| Immunotherapy, Adoptive | 19 | 2022 | 1763 | 1.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 15 | 2024 | 5319 | 1.030 |
Why?
|
| Interleukin-2 | 8 | 2024 | 842 | 0.980 |
Why?
|
| Lung Neoplasms | 21 | 2024 | 11538 | 0.920 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 4 | 2022 | 69 | 0.590 |
Why?
|
| Antigen Presentation | 7 | 2022 | 272 | 0.580 |
Why?
|
| Polyethylene Glycols | 4 | 2020 | 615 | 0.550 |
Why?
|
| HLA-A Antigens | 2 | 2018 | 102 | 0.540 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 309 | 0.530 |
Why?
|
| Antineoplastic Agents, Immunological | 6 | 2020 | 1249 | 0.500 |
Why?
|
| Adoptive Transfer | 4 | 2020 | 446 | 0.490 |
Why?
|
| Immunotherapy | 11 | 2021 | 3341 | 0.480 |
Why?
|
| Immunologic Memory | 4 | 2020 | 374 | 0.470 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2020 | 1016 | 0.460 |
Why?
|
| Skin Neoplasms | 9 | 2022 | 4654 | 0.440 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2021 | 1062 | 0.430 |
Why?
|
| Cancer Vaccines | 4 | 2021 | 697 | 0.430 |
Why?
|
| Lymphocyte Activation | 12 | 2023 | 1688 | 0.410 |
Why?
|
| Tumor Microenvironment | 15 | 2022 | 2864 | 0.400 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 202 | 0.370 |
Why?
|
| Ipilimumab | 5 | 2021 | 710 | 0.360 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2011 | 219 | 0.360 |
Why?
|
| Neoplasms | 14 | 2022 | 15193 | 0.350 |
Why?
|
| Programmed Cell Death 1 Receptor | 8 | 2020 | 1048 | 0.340 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2018 | 235 | 0.340 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2022 | 3251 | 0.330 |
Why?
|
| Cytotoxicity, Immunologic | 7 | 2019 | 675 | 0.320 |
Why?
|
| Humans | 86 | 2024 | 261506 | 0.320 |
Why?
|
| Cell Line, Tumor | 20 | 2021 | 14551 | 0.320 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2024 | 1724 | 0.320 |
Why?
|
| CTLA-4 Antigen | 5 | 2019 | 657 | 0.310 |
Why?
|
| Tumor Escape | 2 | 2021 | 251 | 0.310 |
Why?
|
| Pancreatic Neoplasms | 5 | 2024 | 5061 | 0.290 |
Why?
|
| Rare Diseases | 2 | 2020 | 351 | 0.290 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2021 | 5178 | 0.270 |
Why?
|
| B7-H1 Antigen | 3 | 2023 | 1022 | 0.270 |
Why?
|
| Peptides | 5 | 2021 | 1479 | 0.270 |
Why?
|
| CD58 Antigens | 2 | 2023 | 10 | 0.260 |
Why?
|
| Neoplasms, Second Primary | 3 | 2023 | 1350 | 0.260 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2020 | 673 | 0.250 |
Why?
|
| Monitoring, Immunologic | 2 | 2021 | 47 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 4 | 2021 | 4975 | 0.240 |
Why?
|
| Uveal Neoplasms | 2 | 2018 | 176 | 0.230 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2017 | 1283 | 0.230 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 709 | 0.230 |
Why?
|
| Paraffin Embedding | 2 | 2021 | 226 | 0.220 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2020 | 186 | 0.220 |
Why?
|
| Epitopes | 3 | 2021 | 685 | 0.210 |
Why?
|
| Mutation | 12 | 2021 | 15179 | 0.210 |
Why?
|
| Ovarian Neoplasms | 3 | 2024 | 4638 | 0.200 |
Why?
|
| Interferon-gamma | 4 | 2021 | 1144 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 6 | 2022 | 4367 | 0.200 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2022 | 75 | 0.200 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2021 | 24 | 0.200 |
Why?
|
| Antigens, Bacterial | 2 | 2021 | 354 | 0.200 |
Why?
|
| Biomarkers, Tumor | 7 | 2021 | 10331 | 0.200 |
Why?
|
| Mice | 18 | 2023 | 34495 | 0.190 |
Why?
|
| Melanoma, Experimental | 3 | 2020 | 368 | 0.190 |
Why?
|
| CD28 Antigens | 2 | 2020 | 202 | 0.190 |
Why?
|
| CD3 Complex | 1 | 2022 | 314 | 0.190 |
Why?
|
| HLA Antigens | 2 | 2021 | 546 | 0.190 |
Why?
|
| Aurora Kinase B | 1 | 2020 | 68 | 0.190 |
Why?
|
| HLA-A2 Antigen | 4 | 2017 | 159 | 0.190 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2021 | 160 | 0.190 |
Why?
|
| Interleukins | 2 | 2020 | 325 | 0.180 |
Why?
|
| Lymphocyte Depletion | 1 | 2021 | 264 | 0.180 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2017 | 182 | 0.180 |
Why?
|
| Prognosis | 8 | 2021 | 21713 | 0.180 |
Why?
|
| Animals | 22 | 2023 | 59536 | 0.180 |
Why?
|
| Transcriptome | 4 | 2022 | 1859 | 0.180 |
Why?
|
| Aurora Kinase A | 1 | 2020 | 202 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2018 | 582 | 0.170 |
Why?
|
| GTP Phosphohydrolases | 1 | 2021 | 336 | 0.170 |
Why?
|
| Colitis | 1 | 2022 | 340 | 0.170 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 105 | 0.170 |
Why?
|
| Interleukin-9 | 1 | 2018 | 37 | 0.160 |
Why?
|
| Prodrugs | 1 | 2020 | 217 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2022 | 1146 | 0.160 |
Why?
|
| B7 Antigens | 1 | 2019 | 84 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2022 | 15862 | 0.160 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2018 | 75 | 0.160 |
Why?
|
| RNA Editing | 1 | 2018 | 92 | 0.160 |
Why?
|
| Cytokines | 5 | 2020 | 2809 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2018 | 129 | 0.160 |
Why?
|
| ErbB Receptors | 4 | 2021 | 2295 | 0.160 |
Why?
|
| Mycoplasma | 1 | 1997 | 14 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2018 | 198 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2020 | 2326 | 0.150 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 5112 | 0.150 |
Why?
|
| Mitogens | 1 | 1997 | 75 | 0.150 |
Why?
|
| Superantigens | 1 | 1997 | 29 | 0.150 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 470 | 0.150 |
Why?
|
| Female | 30 | 2024 | 141928 | 0.150 |
Why?
|
| Antibodies | 3 | 2015 | 838 | 0.150 |
Why?
|
| Serine Proteases | 1 | 2017 | 20 | 0.150 |
Why?
|
| Human papillomavirus 16 | 1 | 2019 | 256 | 0.150 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2017 | 56 | 0.150 |
Why?
|
| Colorectal Neoplasms | 2 | 2024 | 3578 | 0.150 |
Why?
|
| Receptors, Interferon | 1 | 2016 | 44 | 0.140 |
Why?
|
| Immune System | 1 | 2018 | 279 | 0.140 |
Why?
|
| RNA, Long Noncoding | 1 | 2022 | 598 | 0.140 |
Why?
|
| Bacteria | 1 | 2021 | 611 | 0.140 |
Why?
|
| Microscopy | 1 | 2017 | 182 | 0.140 |
Why?
|
| Middle Aged | 21 | 2024 | 86204 | 0.140 |
Why?
|
| Antigen-Presenting Cells | 2 | 2014 | 284 | 0.140 |
Why?
|
| Pneumonia | 1 | 2022 | 751 | 0.140 |
Why?
|
| Papillomavirus Vaccines | 1 | 2019 | 195 | 0.140 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2020 | 612 | 0.140 |
Why?
|
| Chromatin | 1 | 2021 | 942 | 0.140 |
Why?
|
| Membrane Transport Proteins | 1 | 2017 | 244 | 0.130 |
Why?
|
| Signal Transduction | 4 | 2019 | 11965 | 0.130 |
Why?
|
| Neutrophils | 1 | 2020 | 835 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 7 | 2020 | 6942 | 0.130 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2015 | 31 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2017 | 242 | 0.130 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 486 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 882 | 0.130 |
Why?
|
| Osteosarcoma | 1 | 2022 | 929 | 0.130 |
Why?
|
| Glycolysis | 1 | 2018 | 519 | 0.130 |
Why?
|
| Histone Acetyltransferases | 1 | 2017 | 411 | 0.130 |
Why?
|
| Heterografts | 1 | 2017 | 733 | 0.130 |
Why?
|
| Clonal Evolution | 1 | 2017 | 253 | 0.130 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 315 | 0.130 |
Why?
|
| Flow Cytometry | 1 | 2021 | 3033 | 0.130 |
Why?
|
| Dendritic Cells | 1 | 2021 | 1085 | 0.130 |
Why?
|
| src-Family Kinases | 1 | 2017 | 478 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 1033 | 0.120 |
Why?
|
| Protein Binding | 5 | 2018 | 3438 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2020 | 8873 | 0.120 |
Why?
|
| Male | 22 | 2024 | 123000 | 0.120 |
Why?
|
| Lymphocyte Count | 3 | 2020 | 486 | 0.110 |
Why?
|
| Phospholipases A | 2 | 2003 | 52 | 0.110 |
Why?
|
| Mice, Knockout | 3 | 2017 | 5710 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2020 | 3821 | 0.110 |
Why?
|
| Crohn Disease | 1 | 2016 | 351 | 0.110 |
Why?
|
| Genomics | 2 | 2022 | 2738 | 0.110 |
Why?
|
| Myeloblastin | 1 | 2012 | 64 | 0.110 |
Why?
|
| Leukocyte Elastase | 1 | 2012 | 70 | 0.110 |
Why?
|
| Lymphocyte Subsets | 1 | 2012 | 137 | 0.110 |
Why?
|
| Biomarkers | 6 | 2021 | 5047 | 0.110 |
Why?
|
| Melanocytes | 3 | 2021 | 219 | 0.110 |
Why?
|
| Interleukin-1alpha | 1 | 2012 | 56 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 984 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 854 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2012 | 173 | 0.100 |
Why?
|
| Gene Expression | 2 | 2017 | 3570 | 0.100 |
Why?
|
| Salvage Therapy | 1 | 2019 | 2054 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2012 | 300 | 0.100 |
Why?
|
| Combined Modality Therapy | 6 | 2021 | 8865 | 0.100 |
Why?
|
| Cell Proliferation | 6 | 2021 | 7226 | 0.090 |
Why?
|
| Cohort Studies | 5 | 2022 | 9244 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2021 | 2819 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 1946 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 986 | 0.090 |
Why?
|
| NF-kappa B | 1 | 2017 | 1549 | 0.090 |
Why?
|
| Cross Reactions | 1 | 2011 | 266 | 0.090 |
Why?
|
| Aged | 12 | 2022 | 70117 | 0.090 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 7789 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 980 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 4 | 2020 | 5395 | 0.090 |
Why?
|
| Thoracic Surgery, Video-Assisted | 2 | 2022 | 209 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2022 | 2576 | 0.090 |
Why?
|
| Thoracotomy | 2 | 2022 | 220 | 0.090 |
Why?
|
| MART-1 Antigen | 2 | 2021 | 105 | 0.090 |
Why?
|
| Coculture Techniques | 2 | 2021 | 626 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2020 | 4078 | 0.080 |
Why?
|
| Lymphoma | 1 | 2017 | 1467 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2022 | 2947 | 0.080 |
Why?
|
| Models, Biological | 1 | 2017 | 3254 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2016 | 1154 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2330 | 0.080 |
Why?
|
| Treatment Outcome | 8 | 2021 | 32848 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 3230 | 0.080 |
Why?
|
| Clinical Trials as Topic | 3 | 2012 | 3719 | 0.080 |
Why?
|
| Apoptosis | 4 | 2020 | 7591 | 0.070 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 1215 | 0.070 |
Why?
|
| Tumor Burden | 3 | 2021 | 1987 | 0.070 |
Why?
|
| Adult | 10 | 2021 | 77950 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 7548 | 0.070 |
Why?
|
| Heparan Sulfate Proteoglycans | 2 | 2003 | 54 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 3022 | 0.070 |
Why?
|
| Cells, Cultured | 4 | 2020 | 5637 | 0.070 |
Why?
|
| Interleukin-12 | 2 | 2018 | 253 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2011 | 1732 | 0.070 |
Why?
|
| Pneumonectomy | 2 | 2022 | 831 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2021 | 2292 | 0.070 |
Why?
|
| DNA Copy Number Variations | 2 | 2023 | 1516 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2021 | 4557 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 29902 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 5437 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 2594 | 0.060 |
Why?
|
| Arachidonic Acid | 2 | 2003 | 118 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 4757 | 0.060 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2022 | 78 | 0.050 |
Why?
|
| Disease Progression | 3 | 2019 | 6682 | 0.050 |
Why?
|
| Autoantigens | 1 | 2003 | 234 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2017 | 1681 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 15694 | 0.050 |
Why?
|
| Spatial Analysis | 1 | 2021 | 35 | 0.050 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 14289 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 14889 | 0.050 |
Why?
|
| Neutrophil Activation | 1 | 2020 | 34 | 0.050 |
Why?
|
| Perioperative Period | 1 | 2021 | 155 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2018 | 3005 | 0.050 |
Why?
|
| Gene Knockout Techniques | 1 | 2021 | 276 | 0.050 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2021 | 245 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 4849 | 0.040 |
Why?
|
| Lung | 2 | 2022 | 3151 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2022 | 1053 | 0.040 |
Why?
|
| Safety | 1 | 2021 | 465 | 0.040 |
Why?
|
| Mesoderm | 1 | 2021 | 404 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 371 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 484 | 0.040 |
Why?
|
| Cyclin I | 1 | 2018 | 8 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 10035 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 406 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 490 | 0.040 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 275 | 0.040 |
Why?
|
| Adenosine | 1 | 2020 | 289 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 826 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 555 | 0.040 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2018 | 53 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 1382 | 0.040 |
Why?
|
| Leishmania | 1 | 1998 | 24 | 0.040 |
Why?
|
| Chemokine CXCL10 | 1 | 2018 | 105 | 0.040 |
Why?
|
| Receptors, Interleukin-21 | 1 | 2017 | 13 | 0.040 |
Why?
|
| Proteogenomics | 1 | 2018 | 87 | 0.040 |
Why?
|
| HLA-A24 Antigen | 1 | 2017 | 13 | 0.040 |
Why?
|
| Topotecan | 1 | 2018 | 239 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2021 | 323 | 0.040 |
Why?
|
| Young Adult | 3 | 2021 | 21445 | 0.040 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2017 | 88 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 651 | 0.040 |
Why?
|
| Nucleocytoplasmic Transport Proteins | 1 | 2017 | 22 | 0.040 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2017 | 33 | 0.040 |
Why?
|
| Neutrophil Infiltration | 1 | 2017 | 109 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2021 | 739 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 1998 | 171 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 1997 | 385 | 0.040 |
Why?
|
| Dimerization | 1 | 1997 | 304 | 0.040 |
Why?
|
| Survival Rate | 2 | 2020 | 12221 | 0.040 |
Why?
|
| 3' Untranslated Regions | 1 | 2018 | 343 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 1130 | 0.040 |
Why?
|
| Antigens | 1 | 1997 | 292 | 0.040 |
Why?
|
| Zinc | 1 | 1997 | 188 | 0.040 |
Why?
|
| Drug Resistance | 1 | 1998 | 587 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 905 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2016 | 394 | 0.030 |
Why?
|
| Time Factors | 2 | 2021 | 12926 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2022 | 1048 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2018 | 798 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2021 | 12873 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2017 | 318 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2017 | 403 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2020 | 9180 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2023 | 2203 | 0.030 |
Why?
|
| Software | 1 | 2022 | 1321 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2015 | 257 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 388 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 368 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2016 | 263 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 1294 | 0.030 |
Why?
|
| Methotrexate | 1 | 1998 | 999 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 1271 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 1085 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 7222 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2803 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 1538 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 1869 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 2315 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 289 | 0.030 |
Why?
|
| K562 Cells | 1 | 2014 | 338 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2017 | 4233 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 212 | 0.030 |
Why?
|
| Histones | 1 | 2021 | 1466 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2015 | 280 | 0.030 |
Why?
|
| Group II Phospholipases A2 | 2 | 2003 | 12 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2021 | 4307 | 0.030 |
Why?
|
| Phospholipases A2 | 2 | 2003 | 43 | 0.030 |
Why?
|
| Biopsy | 1 | 2021 | 3443 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1077 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 726 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2015 | 829 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 3154 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 10001 | 0.030 |
Why?
|
| Cross-Priming | 1 | 2012 | 39 | 0.030 |
Why?
|
| Indoles | 2 | 2012 | 1009 | 0.030 |
Why?
|
| Protein Transport | 1 | 2015 | 734 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 1313 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 67 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2022 | 2669 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2016 | 1038 | 0.030 |
Why?
|
| Muromonab-CD3 | 1 | 2011 | 19 | 0.030 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2011 | 34 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2015 | 850 | 0.020 |
Why?
|
| Receptors, OX40 | 1 | 2011 | 50 | 0.020 |
Why?
|
| Exome | 1 | 2016 | 1239 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 848 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2017 | 1648 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 324 | 0.020 |
Why?
|
| Antilymphocyte Serum | 1 | 2011 | 228 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3890 | 0.020 |
Why?
|
| Obesity | 1 | 2023 | 2884 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2022 | 5159 | 0.020 |
Why?
|
| Adolescent | 2 | 2021 | 31252 | 0.020 |
Why?
|
| Cell Line | 1 | 1997 | 5114 | 0.020 |
Why?
|
| Telomere | 1 | 2012 | 505 | 0.020 |
Why?
|
| Proteins | 1 | 1997 | 1963 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 671 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2012 | 825 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2022 | 37905 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 1914 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 6009 | 0.020 |
Why?
|
| RNA | 1 | 2012 | 1013 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 1271 | 0.020 |
Why?
|
| Binding Sites | 2 | 2003 | 2171 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 3569 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 13658 | 0.020 |
Why?
|
| Risk Factors | 1 | 2023 | 17523 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 3890 | 0.020 |
Why?
|
| Detergents | 1 | 2003 | 34 | 0.010 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 1879 | 0.010 |
Why?
|
| Receptors, Phospholipase A2 | 1 | 2003 | 5 | 0.010 |
Why?
|
| United States | 1 | 2021 | 15433 | 0.010 |
Why?
|
| Heparitin Sulfate | 1 | 2003 | 35 | 0.010 |
Why?
|
| Brain | 1 | 2017 | 4113 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2012 | 1823 | 0.010 |
Why?
|
| Phosphatidylserines | 1 | 2003 | 68 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2003 | 208 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2003 | 629 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2003 | 392 | 0.010 |
Why?
|
| Vimentin | 1 | 2003 | 253 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2012 | 6150 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 7702 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 402 | 0.010 |
Why?
|
| Tritium | 1 | 1999 | 200 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 862 | 0.010 |
Why?
|
| Acyltransferases | 1 | 1999 | 62 | 0.010 |
Why?
|
| Organophosphorus Compounds | 1 | 1999 | 101 | 0.010 |
Why?
|
| Ceramides | 1 | 1999 | 95 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 1999 | 302 | 0.010 |
Why?
|
| Coenzymes | 1 | 1998 | 16 | 0.010 |
Why?
|
| Benzenesulfonates | 1 | 1999 | 195 | 0.010 |
Why?
|
| Trypsin | 1 | 1998 | 140 | 0.010 |
Why?
|
| Urea | 1 | 1999 | 290 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1998 | 611 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1998 | 469 | 0.010 |
Why?
|
| Fatty Acids | 1 | 1999 | 448 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1998 | 844 | 0.010 |
Why?
|
| Point Mutation | 1 | 1998 | 769 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 2489 | 0.010 |
Why?
|
| Kinetics | 1 | 1998 | 2049 | 0.010 |
Why?
|
| Imidazoles | 1 | 1999 | 999 | 0.010 |
Why?
|
| Transfection | 1 | 1998 | 2944 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 2927 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1998 | 6089 | 0.010 |
Why?
|